References

References

[1] KJAERGAARD J, HOKLAND M E, AGGER R, et al.Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals[J].Cancer immunol immunotherapy, 2000, 48 (10): 550-560.

[2] KUMAR A, SURYADEVARA N, HILL T M, et al.Natural killer T cells: an ecological evolutionary developmental biology perspective[J].Frontiersin immunology, 2017, 8:1858.

[3] BRIGL M, BRENNER M B.CD1: antigen presentation and T cell function[J].Annual review of immunology, 2004, 22:817-890.

[4] BRIGL M, TATITURI R V, WATTS G F, et al.Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection[J].Journal of experimental medicine, 2011, 208(6):1163-1177.

[5] BENDELAC, A.CD1 recognition by mouse NK1+ T lymphocytes[J].Science, 1996, 268,863-865.

[6] PAGET C, MALLEVAEY T, SPEAK A O, et al.Activation of invariant NKT cells by toll-like receptor 9-stimulated dendritic cells requires type I interferon and charged glycosphingolipids[J].Immunity, 2007, 27(4):597-609.

[7] PAGET C, IVANOV S, FONTAINE J, et al.Interleukin-22 is produced by invariant natural killer T lymphocytes during influenza A virus infection: potential role in protection against lung epithelial damages[J].Journal of biology chemistry, 2012, 287(12):8816-8829.

[8] PAGET C, IVANOV S, FONTAINE J, et al.Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia[J].Journal of immunology, 2011, 186(10):5590-5602.

[9] KOK W L, DENNEY L, BENAM K, et al.Pivotal advance: invariant NKT cells reduce accumulation of inflammatory monocytes in the lungs and decrease immune-pathology during severe influenza A virus infection[J].Journal of leukocyte biology, 2012, 91(3):357-368.

[10] KUMAR A, SURYADEVARA N, Hill T M, et al.Natural killer T cells: an ecological evolutionary developmental biology perspective[J].Frontiers in immunol, 2017, 8:1858.

[11] TYZNIK A J, TUPIN E, NAGARAJAN N A, et al.The mechanism of invariant NKT cell responses to viral danger signals[J].Journal of immunology, 2008, 181(7):4452-4456.

[12] WESLEY J D, TESSMER M S, CHAUKOS D, et al.NK cell-like behavior of Valpha14i NK T cells during MCMV infection[J].PLoS pathogens, 2008, 4(7): e1000106.

[13] TANIGUCHI M, HARADA M, DASHTSOODOL N, et al.Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy[C]//Proceedings of the Japan Academy, Series B, Physical and biological sciences, 2015, 91(7):292-304.

[14] BRIGL M, BRY L, KENT S C, et al.Mechanism of CD1drestricted natural killer T cell activation during microbial infection[J].Nature immunology, 2003, 4(12):1230-1237.

[15] TANIGUCHI M, SEINO K, NAKAYAMA T.The NKT cell system: bridging innate and acquired immunity[J].Nature immunology, 2003, 4:1164-1165.

[16] FUJII S, SHIMIZU K, HEMMI H, et al.Glycolipidα-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice[C]//Proceedings of the National Academy of Sciences of the United States of America,2006, 103:11252-11257.

[17] LIPPITZ B E.Cytokine patterns in patients with cancer: a systematic review[J].Lancet oncology, 2013, 14: e218-e228.

[18] FERNIE A R, CARRARI F, SWEETLOVE L J.Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport[J].Current opinion plant biology, 2004,7(3):254-261.

[19] FOX C J, HAMMERMAN P S, THOMPSON C B.Fuel feeds function: energy metabolism and the T-cell response[J].Nature review immunology, 2005, 5(11): 844-852.

[20] VANDER HEIDEN M G, CANTLEY L C, et al.Understanding the Warburg effect: the metabolic requirements of cell proliferation[J].Science, 2009, 324(5930): 1029-1033.

[21] WAHL D R, BYERSDORFER C A, FERRARA J L, et al.Distinct metabolic programs in activated T cells: opportunities for selective immunomodulation[J].Immunology review,2012, 249(1): 104-115.

[22] DE BOER R J, HOMANN D, PERELSON A S.Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection[J].Journal of immunology, 2003, 171(8): 3928-3935.

[23] PEARCE E L, WALSH M C, CEJAS P J, et al.Enhancing CD8 T-cell memory by modulating fatty acid metabolism[J].Nature, 2009, 460(7251): 103-107.

[24] LOCHNER M, BEROD L, SPARWASSER T.Fatty acid metabolism in the regulation of T cell function[J].Trends immunology, 2015, 36(2): 81-91.

[25] FRASER K A, SCHENKEL J M, JAMESON S C, et al.Preexisting high frequencies of memory CD8+ T cells favor rapid memory differentiation and preservation of proliferative potential upon boosting[J].Immunity, 2013, 39(1): 171-183.

[26] MOLON B, CALÌ B, VIOLA A.T cells and cancer: how metabolism shapes immunity[J].Front immunology, 2016, 7: 20.

[27] FREY A B.Suppression of T cell responses in the tumor microenvironment[J].Vaccine,2015, 33(51): 7393-7400.

[28] VINAY D S, RYAN E P, PAWELEC G, et al.Immune evasion in cancer: mechanistic basis and therapeutic strategies[J].Seminars in cancer biology, 2015, 35(Suppl): S185-S198.

[29] KIM R, EMI M, TANABE K.Cancer immunoediting from immune surveillance to immune escape[J].Immunology, 2007, 121(1): 1-14.

[30] GAJEWSKI T F, FUERTES M, SPAAPEN R, et al.Molecular profifiling to identify relevant immune resistance mechanisms in the tumor microenvironment[J].Current opinion in immunology, 2011, 23(2): 286-292.

[31] HERBEL C, PATSOUKIS N, BARDHAN K, et al.Clinical signifificance of T cell metabolic reprogramming in cancer[J].Clinical and translational medicine, 2016, 5(1): 29.

[32] CHANG C H, QIU J, O’SULLIVAN D, et al.Metabolic competition in the tumor microenvironment is a driverof cancer progression[J].Cell, 2015, 162(6): 1229-1241.

[33] ZHANG Y, ERTL H C.Starved and asphyxiated: how can CD8+ T cells within a tumor microenvironment prevent tumor progression[J].Front of immunology, 2016, 7: 32.

[34] NAKAIGAWA N, KONDO K, UENO D, et al.The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy[J].BMC cancer, 2017, 17(1): 39.

[35] MAETA N, TAMURA K, TAKEMITSU H, et al.Lymphokine-activated killer cell transplantation after anti-cancer treatment in two aged cats[J].Open veterinary journal,2019, 9(2):147-150.

[36] BUDHU S, LOIKE J D, PANDOLFI A, et al.CD8+T cell concentration determines their effificiency in killing cognate antigenexpressing syngeneic mammalian cells in vitro and in mouse tissues[J].Journal of experimental medicine, 2010, 207:223-235.

[37] DUNN G P, OLD L J, SCHREIBER R D.The three Es of cancer immunoediting[J].Annual review of immunology, 2004, 22:329-360.

[38] EVANS C M, JENNER R G .Transcription factor interplay in T helper cell differentiation[J].Briefings in functional genomics, 2013, 12(6):499-511.

[39] ZHU J, JANKOVIC D, OLER A J, et al.The transcription factor T-bet is induced by multiple pathways and prevents an endogenous T helper-2 program during T helper-1 responses[J].Immunity, 2012, 37(4):660-673.

[40] Wei L, Vahedi G, Sun H W, et al.Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation[J].Immunity, 2010, 32(6):840-851.

[41] MIKHAK Z, FLEMING C M, MEDOFF B D, et al.STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells[J].Journal of immunology, 2006,176(8):4959-4967.

[42] GEGINAT J, PARONI M, MAGLIE S, et al.Plasticity of human CD4 T cell subsets[J].Frontiers in immunology, 2014(5):630.

[43] STENZINGER A, ENDRIS V, PFARR N, et al.Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm[J].Oncotarget, 2014, 5:6404-6413.

[44] JOHANSSON M, DENARDO D G, COUSSENS L M.Polarized immune responses differentially regulate cancer development[J].Immunological reviews, 2008, 222:145-154.

[45] KEMP R A, RONCHESE F.Tumor-specifific Tc1, but not Tc2, cells deliver protective antitumor immunity[J].Journal of immunology, 2001, 167:6497-6502.

[46] LI Z, ZHANG Y, SUN B.Current understanding of Th2 cell differentiation and function[J].Protein cell, 2011, 2(8):604-611.

[47] TANAKA K, BARMINA O, SANDERS L E, et al.Evolution of sex-specific traits through changes in HOX-dependent doublesex expression[J].PLoS biology, 2011, 9: e1001131.

[48] MIYAHARA Y, ODUNSI K, CHEN W, et al.Generation and regulation of human CD4+IL-17-producing T cells in ovarian cancer[C]//Proceedings of the National Academy of Sciences of the United States of America, 2008, 105:15505-15510.

[49] KRYCZEK I, BANERJEE M, CHENG P, et al.Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments[J].Blood,2009, 114:1141-1149.

[50] STRITESKY G L, YEH N, KAPLAN M H.IL-23 promotes maintenance but not commitment to the Th17 lineage[J].Journal of immunology, 2008, 181:5948-5955.

[51] MAILER R K, JOLY A L, LIU S, et al.IL-1beta promotes Th17 differentiation by inducing alternative splicing of FOXP3[J].Scientific reports, 2015, 5:14674.

[52] ZHANG S, TAKAKU M, ZOU L, et al.Reversing SKI-SMAD4-mediated suppression is essential for TH17 cell differentiation[J].Nature, 2017, 551:105-109.

[53] QIN H, WANG L, FENG T, et al.TGF-beta promotes Th17 cell development through inhibition of SOCS3[J].Journal of immunology, 2009, 183:97-105.

[54] KIM H S, JANG S W, LEE W, et al.PTEN drives Th17 cell differentiation by preventing IL-2 production[J].Journal of experimental medicine, 2017, 214:3381-3398.

[55] YANG X O, PANOPOULOS A D, NURIEVA R, et al.STAT3 regulates cytokine-mediated generation of inflammatory helper T cells[J].Journal of biological chemistry, 2007,282:9358-9363.

[56] O’SHEA J J, PAUL W E.Mechanisms underlying lineage commitment and plasticity of helper CD4+T cells[J].Science, 2010, 327:1098-1102.

[57] CARR T M, WHEATON J D, HOUTZ G M, et al.JunB promotes Th17 cell identity and restrains alternative CD4(+) T-cell programs during inflammation[J].Nature communication,2017, 8:301.

[58] MCGEACHY M J, BAK-JENSEN K S, CHEN Y, et al.TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology[J].Nature immunology, 2007, 8:1390-1397.

[59] KINUGASA T, SAKAGUCHI T, GU X, et al.Claudins regulate the intestinal barrier in response to immune mediators[J].Gastroenterology, 2000, 118:1001-1011.

[60] KORN T, BETTELLI E, OUKKA M, et al.IL-17 and Th17 Cells[J].Annual review in immunology, 2009, 27:485-517.

[61] TAN W, HUANG W, ZHONG Q, et al.IL-17 receptor knockout mice have enhanced myelotoxicity and impaired hemopoietic recovery following gamma irradiation[J].Journal of immunology, 2006, 176:6186-6193.

[62] SIEGEMUND S, SCHÜTZE N, FREUDENBERG M A, et al.Production of IL-12, IL-23 and IL-27p28 by bone marrow-derived conventional dendritic cells rather than macrophages after LPS/TLR4-dependent induction by Salmonella Enteritidis[J].Immunobiology, 2007,212:739-750.

[63] OKADA S, PUEL A, CASANOVA J L, et al.Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity[J].Clinical & developmental immunology,2016, 5:e114.

[64] DAVIS S, SCHALLER J.Job’s Syndrome:recurrent, “cold”, staphylococcal abcesses[J].Lancet, 1966, 1:1013-1015.

[65] RUDENSKY A Y, GAVIN M, ZHENG Y.FOXP3 and NFAT: partners in tolerance[J].Cell,2006, 126:253-256.

[66] SAKAGUCHI S, MIYARA M, COSTANTINO C M.FOXP3+ regulatory T cells in the human immune system[J].Nature review of immunology, 2010, 10:490-500.

[67] TANG Q, BLUESTONE J A.The Foxp3+ regulatory T cell: a jack of all trades, master of regulation[J].Nature immunology, 2008, 9:239-244.

[68] WALKER L S, SANSOM D M.The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J].Nature review of immunology, 2011, 11:852-863.

[69] MAEDA Y, NISHIKAWA H, SUGIYAMA D, et al.Detection of self-reactive CD8(+) T cells with an anergic phenotype in healthy individuals[J].Science, 2014, 346:1536-1540.

[70] QURESHI O S, ZHENG Y, NAKAMURA K, et al.Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4[J].Science, 2011, 332:600-603.

[71] COLLISON L W, WORKMAN C J, KUO T T, et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J].Nature, 2007, 450:566-569.

[72] CAO X, CAI S F, FEHNIGER T A, et al.Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance[J].Immunity, 2007, 27:635-646.

[73] KAMADA T, TOGASHI Y, TAY C, et al.PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[C]//Proceedings of the National Academy of Sciences of the United States of America, 2019, 116:9999-10008.

[74] CAMISASCHI C, CASATI C, RINI F, et al.LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites[J].Journal of immunology, 2010, 184:6545-6551.

[75] MELLOR A L, MUNN D H.IDO expression by dendritic cells: tolerance and tryptophan catabolism[J].Nature review of immunology, 2004, 4:762-774.

[76] MAJ T, WANG W, CRESPO J, et al.Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor[J].Nature immunology,2017, 18:1332-1341.

[77] ABEL A M, YANG C, THAKAR M S, et al.Natural killer cells: development, maturation,and clinical utilization[J].Frontiers in immunology, 2018, 9:1869.

[78] RAJASEKARAN K, RIESE M J, RAO S, et al.Signaling in effector lymphocytes: insights toward safer immunotherapy[J].Frontiers in immunology, 2016, 7:176.

[79] LANIER L L.Up on the tightrope: natural killer cell activation and inhibition[J].Nature immunology, 2008, 9:495-502.

[80] ROSEN D B, ARAKI M, HAMERMAN J A, et al.A structural basis for the association of DAP12 with mouse, but not human, NKG2D[J].Journal of immunology, 2004,173:2470-2478.

[81] SMITH K M, WU J, BAKKER A B, et al.Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors[J].Journal of immunology, 1998, 161:7-10.

[82] ORR M T, SUN J C, HESSLEIN D G, et al.Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infection[J].Journal of experimental medicine, 2009, 206:807-817.

[83] STABILE H, FIONDA C, GISMONDI A, et al.Role of distinct natural killer cell subsets in anticancer response[J].Frontiers in immunology, 2017, 8:293.

[84] FAURIAT C, LONG E O, LJUNGGREN H G, et al.Regulation of human NK-cell cytokine and chemokine production by target cell recognition[J].Blood, 2010.115:2167-2176.

[85] FREEMAN B E, RAUE H P, HILL A B, et al.Cytokine-mediated activation of NK cells during viral infection[J].Journal of virology, 2015, 89:7922-7931.

[86] KRZEWSKI K, STROMINGER J L.The killer’s kiss: the many functions of NK cell immunological synapses[J].Current opinion of cell biology, 2008, 20:597-605.

[87] CROWDER R N, EL-DEIRY W S.Caspase-8 regulation of TRAIL-mediated cell death[J].Experimental oncology, 2012, 34:160-164.

[88] WOLF B B, SCHULER M, ECHEVERRI F, et al.Caspase-3 is the primary activator of apoptotic DNA fragmentation via DNA fragmentation factor-45/inhibitor of caspase-activated DNase inactivation[J].Journal of biology chemistry, 1999, 274:30651-30656.

[89] BAO Q, SHI Y.Apoptosome: a platform for the activation of initiator caspases[J].Cell death and differentiation, 2007, 14:56-65.

[90] CHEN X, TRIVEDI P P, GE B, et al.Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity[C]//Proceedings of the National Academy of Sciences of the United States of America, 2007, 104:6329-6334.

[91] STINCHCOMBE J C, MAJOROVITS E, BOSSI G, et al.Centrosome polarization delivers secretory granules to the immunological synapse[J].Nature, 2006, 443:462-465.

[92] COOK K D, WAGGONER S N, WHITMIRE J K.NK cells and their ability to modulate T cells during virus infections[J].Critical review of immunology, 2014, 34:359-388.

[93] LEE H K, KIM Y G, KIM J S, et al.Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling[J].Cancer letter, 2016, 378(2):142-149.

[94] LINN Y C, LAU L C, HUI K M.Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts[J].British journal of haematology, 2002, 116(1):78-86.

[95] SCHMIDT T L, NEGRIN R S, CONTAG C H.A killer choice for cancer immunotherapy[J].Immunology research, 2014, 58(2-3):300-306.

[96] PIEVANI A, BELUSSI C, KLEIN C, et al.Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies[J].Blood, 2011, 117(2):510-518.

[97] LINN Y C, WANG S M, HUI K M.Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays[J].Experimental hematology, 2005,33(6):671-681.(https://www.daowen.com)

[98] SANGIOLO D.Cytokine induced killer cells as promising immunotherapy for solid tumors[J].Journal of cancer, 2011, 2:363-368.

[99] NTRONA M, FRANCESCHETTI M, CIOCCA A, et al.Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation[J].Bone marrow transplant, 2006,38(9):621-627.

[100] HAYES M P, WANG J, NORCROSS M A.Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes[J].Blood, 1995, 86(2):646-650.

[101] OCHOA A C, GROMO G, ALTER B J, et al.Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta[J].Journal of immunology, 1987, 138(8):2728-2733.

[102] LEEMHUIS T, WELLS S, SCHEFFOLD C, et al.A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma[J].Biology blood marrow transplant, 2005, 11(3):181-187.

[103] BAKER J, VERNERIS M R, ITO M, et al.Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production[J].Blood, 2001, 97(10):2923-2931.

[104] COHEN J E, MERIMS S, FRANK S, et al.Adoptive cell therapy: past, present and future[J].Immunotherapy, 2017, 9(2):183-196.

[105] RETTINGER E, KUCI S, NAUMANN I, et al.The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells[J].Cytotherapy, 2012, 14(1):91-103.

[106] MOSINSKA P, GABRYELSKA A, ZASADA M, et al.Dual functional capability of dendritic cells—cytokine-induced killer cells in improving side effects of colorectal cancer therapy[J].Frontiers of pharmacology, 2017, 8:126.

[107] LINN Y C, NIAM M, CHU S, et al.The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies[J].Bone marrow transplant, 2012, 47(7):957-966.

[108] ZHANG Z, ZHAO X, ZHANG T, et al.Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood[J].Cytotherapy, 2015, 17(1):86-97.

[109] NIU Q, WANG W, LI Y, et al.Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies[J].International immunopharmacology, 2011, 11(4):449-456.

[110] SANGIOLO D, MARTINUZZI E, TODOROVIC M, et al.Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells:implications for their infusion across major HLA barriers[J].International immunology, 2008,20:841-848.

[111] LEEMHUIS T, WELLS S, SCHEFFOLD C, et al.A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma[J].Biology blood marrow transplant, 2005, 11:181-187.

[112] LINN Y C, LAU S K, LIU B H, et al.Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell[J].Immunology, 2009, 126:423-435.

[113] NISHIMURA R, BAKER J, BEILHACK A, et al.In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity[J].Blood, 2008, 112:2563-2574.

[114] JIANG J, WU C, LU B.Cytokine-induced killer cells promote antitumor immunity[J].Journal of translate medicine, 2013, 11:83.

[115] EDINGER M, CAO Y A, VERNERIS M R, et al.Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging[J].Blood, 2003,101:640-648.

[116] GUO Y, HAN W.Cytokine-induced killer (CIK) cells: from basic research to clinical translation[J].Chinese journal of cancer, 2015, 34(3):99-107.

[117] LEE J H, LIM Y S, YEON J E, et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J].Gastroenterology, 2015,148(7):1383-1391.

[118] WANG H, LIU A, BO W, et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systemic review and meta-analysis[J].Digestive and liver disease, 2016, 48(11):1275-1282.

[119] LI X, DAI D, SONG X, et al.A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma[J].Clinical research hepatol gastroenterol, 2014, 38(5):583-591.

[120] MA Y, XU Y C, TANG L, et al.Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety[J].Experimental hematol oncology, 2012,1(1):11.

[121] ZHANG J, ZHU L, DU H, et al.Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study[J].Biomed pharmacother, 2015, 70:248-252.

[122] ZHANG L, YANG X, SUN Z, et al.Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer[J].Oncology letter, 2016,11(4):2605-2610.

[123] JIA H, TIAN Y, JIANG C G, et al.Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy[J].Experimental therapy medicine, 2016, 11(5):1601-1610.

[124] ZHAO H, WANG Y, YU J, et al.Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial[J].Clinical colorectal cancer, 2016, 15(3):228-235.

[125] LIN T, SONG C, CHUO D Y, et al.Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study[J].Tumour biology, 2016, 37(4):4367-4372.

[126] KONG D S, NAM D H, KANG S H, et al.Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea[J].Oncotarget, 2016, 8(4):7003-7013.

[127] LI H, HUANG L, LIU L B, et al.Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma[J].Cancer immunology immunotherapy, 2017,66(3):299-308.

[128] MADS H A, DAVID S, PER THOR S.Cytotoxic T cells[J].Journal of investigative dermatology, 2006, 126:32-41.

[129] KILGORE N E, FORD M L, MARGOT C D, et al.Defining the parameters necessary for T cell recognition of ligands that vary in potency[J].Immunology research, 2004, 29: 29-40.

[130] LOHR J, KNOECHEL B, JIANG S, et al.The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens.Nature immunology, 2003, 4: 664-669.

[131] GREENWALD R J, FREEMAN G J, SHARPE A H.The B7 family revisited[J].Annual review immunology, 2005, 23: 515-548.

[132] O'SULLIVAN B, THOMAS R.CD40 and dendritic cell function[J].Critical review of immunology, 2003, 23: 83-107.

[133] LADERACH D, WESA A, GALY A.4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12[J].Cell immunology, 2003, 226: 37-44.

[134] TOMIYAMA H, MATSUDA T, TAKIGUCHI M.Differentiation of human CD8+ T cells from a memory to memory/effector phenotype[J].Journal of immunology, 2002, 168:5538-5550.

[135] TOMIYAMA H, TAKATA H, MATSUDA T, et al.Phenotypic classification of human CD8+T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function[J].Europe journal of immunology, 2004, 34: 999-1010.

[136] SOBAO Y, TOMIYAMA H, NAKAMURA S, et al.Visual demonstration of hepatitis C virus-specific memory CD8+ T-cell expansion in patients with acute hepatitis C[J].Hepatology,2001, 33: 287-294.

[137] BECKER J C, VETTER C S, SCHRAMA D, et al.Differential expression of CD28 and CD94/NKG2 on T cells with identical TCR beta variable regions in primary melanoma and sentinel lymph node[J].Europe journal of immunology, 2000, 30: 3699-3706.

[138] BLOTT E J, GRIFFITHS G M.Secretory lysosomes[J].Nature review of molecular cell biology, 2002, 3: 122-131.

[139] TRAPANI J A, SMYTH M J.Functional significance of the perforin/granzyme cell death pathway[J].Nature review of immunology, 2002, 2: 735-747.

[140] SAINT-MEZARD P, BERARD F, DUBOIS B, et al.The role of CD4+ and CD8+ T cells in contact hypersensitivity and allergic contact dermatitis[J].Europe journal of dermatol, 2004,14: 131-138.

[141] GARBOCZI D N, GHOSH P, UTZ U, et al.Structure of the complex between human T cell receptor, viral peptide and HLA-A2[J].Nature, 1996, 384: 134-141.

[142] CAVANI A.Breaking tolerance to nickel[J].Toxicology, 2005, 209: 119-121.

[143] FARZATI B, MAZZIOTTI G, CUOMO G, et al.Hashimoto’s thyroiditis is associated with peripheral lymphocyte activation in patients with systemic sclerosis[J].Clinical experimental rheumatol, 2005, 23: 43-49.

[144] PEDERSEN L O, VETTER C S, MINGARI M C, et al.Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma:a case report[J].Journal of investigative dermatology, 2002, 118: 595-599.

[145] STEITZ J, WENZEL J, GAFFAL E, et al.Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: implications for the pathophysiology of vitiligo[J].Europe Journal of cell biology, 2004, 83: 797-803.

[146] NOVELLINO L, CASTELLI C, PARMIANI G .A listing of human tumor antigens recognized by T cells: march 2004 update[J].Cancer immunology immunotherapy, 2004, 54:187-207.

[147] CASTELLI C, RIVOLTINI L, ANDREOLA G, et al.T cell recognition of melanomaassociated antigens[J].Journal of cell physiology, 2000, 182: 323-331.

[148] LIPOWSKA-BHALLA G, GILHAM D E, HAWKINS R E, et al.Targeted immunotherapy of cancer with CAR T cells: achievements and challenges[J].Cancer immunology immunotherapy,2012, 61(7):953-962.

[149] ZHANG C, LIU J, ZHONG J F, et al.Engineering CAR-T cells[J].Biomark research, 2017,5:22.

[150] LIU J, ZHONG J F, ZHANG X, et al.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies[J].Journal of hematology oncology, 2017, 10(1):35.

[151] TASIAN S K, GARDNER R A.CD19-redirected chimeric antigen receptor-modified T cells:a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)[J].Therapeutic advances in hematology, 2015, 6(5):228-241.

[152] BRIDGEMAN J S, HAWKINS R E, BAGLEY S, et al.The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex[J].Journal of immunology, 2010, 184(12):6938-6949.

[153] LONG A H, HASO W M, SHERN J F, et al.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J].Nature medicine,2015, 21(6):581-590.

[154] KAWALEKAR O U, O’CONNOR R S, FRAIETTA J A, et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J].Immunity, 2016, 44(2):380-390.

[155] TILL B G, JENSEN M C, WANG J, et al.CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results[J].Blood, 2012, 119(17):3940-3950.

[156] MARIN V, PIZZITOLA I, AGOSTONI V, et al.Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors[J].Haematologica, 2010, 95(12):2144-2152.

[157] MORGAN R A, YANG J C, KITANO M, et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Molecular therapy, 2010, 18(4):843-851.

[158] CHMIELEWSKI M, ABKEN H.TRUCKs: the fourth generation of CARs[J].Expert opinion of biology therapy, 2015, 15(8):1145-1154.

[159] PAHLE J, WALTHER W.Vectors and strategies for nonviral cancer gene therapy[J].Expert opinion of biology therapy, 2016, 16(4):443-461.

[160] KAY M A, HE C Y, CHEN Z Y.A robust system for production of minicircle DNA vectors[J].Nature biotechnology, 2010, 28(12):1287-1289.

[161] LEVINE B L.Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells[J].Cancer gene therapy, 2015, 22(2):79-84.

[162] GUEDAN S, CHEN X, MADAR A, et al.ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells[J].Blood, 2014, 124(7):1070-1080.

[163] MCGARRITY G J, HOYAH G, WINEMILLER A, et al.Patient monitoring and follow-up in lentiviral clinical trials[J].Journal of gene medicine, 2013, 15(2):78-82.

[164] BEATTY G L, HAAS A R, MAUS M V, et al.Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies[J].Cancer immunology research, 2014, 2(2):112-120.

[165] HARTMANN J, SCHÜßLER-LENZ M, BONDANZA A, et al.Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts[J].EMBO molecular medicine, 2017, 9(9):1183-1197.

[166] RAMOS C A, SAVOLDO B, TORRANO V, et al.Clinical responses with T lymphocytes targeting malignancy-associated kappa light chains[J].Journal of clinical investigation, 2016,126: 2588-2596.

[167] TURTLE C J, HANAFI L-A, BERGER C, et al.CD19 CAR-T cells of defined CD4+: CD8+composition in adult B cell ALL patients[J].Journal of clinical investigation, 2016, 126:2123-2138.

[168] WANG X, POPPLEWELL L L, WAGNER J R, et al.Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL[J].Blood, 2016, 127: 2980-2990.

[169] LEE D W, KOCHENDERFER J N, STETLER-STEVENSON M, et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J].Lancet, 2015, 385: 517-528.

[170] DEFRANCESCO L.CAR-T’s forge ahead, despite Juno deaths[J].Nature biotechnology,2017, 35: 6-7.

[171] DAVILA M L, RIVIERE I, WANG X, et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia[J].Science translational medicine, 2015, 6: 224ra25.

[172] WANG Y, ZHANG W-Y, HAN Q-W, et al.Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells[J].Clinical immunology, 2014, 155: 160-175.

[173] AHMED N, BRAWLEY V S, HEGDE M, et al.Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J].Journal of clinical oncology, 2015, 33: 1688-1696.

[174] MANTEGAZZA A R, MAGALHAES J G, AMIGORENA S, et al.Presentation of phagocytosed antigens by MHC class I and II Adriana[J].Traffic, 2014, 14(2):135-152.

[175] GOLUBOVSKAYA V, BERAHOVICH R, XU S, et al.Major highlights of the CAR-TCR Summit, Boston[J].Anti-cancer agentsin medicinal chemistry, 2017, 17(10):1344-1350.

[176] WIECZOREK M, ABUALROUS E T, STICHT J.Major histocompatibility complex (MHC)class I and MHC class II proteins: conformational plasticity in antigen presentation[J].Frontiers in immunology, 2017, 8:292.

[177] MEDSKER B, FORNO E, SIMHAN H, et al.Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors[J].Trends pharmacology science, 2016,70(12):773-779.

[178] PARDOLL D M.The blockade of immune slide checkpoints in cancer immunotherapy[J].Nature review cancer, 2012, 12(4):252-264.

[179] HU Z, ZOU Q, SU B.Regulation of T cell immunity by cellular metabolism[J].Frontiers in medicine, 2018, 12(4):463-472.

[180] MAUS M V, JUNE C H, HOSPITAL G .Making better chimeric antigen receptors for adoptive T-cell therapy[J].Science, 2017, 22(8):1875-1884.

[181] UHLÉN M, FAGERBERG L, HALLSTRÖM B M, et al.Tissue-based map of the human proteome[J].Science, 2015, 347(6220):1260419.

[182] HARRIS D T, KRANZ D M.Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors[J].Trends pharmacology science, 2016, 37(3):220-230.

[183] Yang J C.Toxicities associated with adoptive T-cell transfer for cancer[J].Cancer J (Sudbury,Mass), 2015, 21(6):506-509.

[184] BORBULEVYCH O Y, SANTHANAGOPOLAN S M, HOSSAIN M, et al.TCRs used in cancer gene therapy cross-react with MART-1/Melan-A tumor antigens via distinct mechanisms[J].Journal of immunology, 2011, 187(5):2453-2463.

[185] HARRIS D T, HAGER M V, SMITH S N.Comparison of T cell activities mediated by human TCRs and CARs that use the same recognition domains[J].Journal of immunology,2018, 200(3):1088-1100.

[186] XU Y, YANG Z, HORAN L H.A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release[J].Cell discovery, 2018, 4(1):62.

[187] VIGNERON N.Human tumor antigens and cancer immunotherapy[J].Biomed research international, 2015, 2015: 948501.

[188] PING Y, LIU C, ZHANG Y.T-cell receptor-engineered T cells for cancer treatment: current status and future directions[J].Protein cell, 2018, 9(3):254-266.

[189] VAN DEN BERG J H, GOMEZ-EERLAND R, VAN DE WIEL B.Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor[J].Molecular therapy, 2015, 23(9):1541-1550.

[190] VILLENA-VARGAS J, ADUSUMILLI P S.Mesothelin-targeted immunotherapies for malignant pleural mesothelioma[J].Annual cardiothorac surgery, 2012, 1(4):466-471.

[191] SCHMITT T M, AGGEN D H, STROMNES I M.Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection[J].Blood, 2013, 122(3):348-356.

[192] PERNA S K, DE ANGELIS B, PAGLIARA D.Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma[J].Clinical cancer research, 2013, 19(1):106-117.

[193] ZHANG J, WANG L.The emerging world of TCR-T cell trials against cancer: a systematic review[J].Technology cancer research treatment, 2019, 18:1533.